Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions
Lexaria’s patent portfolio has increased to 16 awarded patents protecting its DehydraTECH™ drug delivery platform, with 8 granted in the USA and 8 granted in Australia.
This new Australian patent, together with Australian Patent #2016367036 “Methods for formulating orally ingestible compositions comprising lipophilic active agents” announced on August 15, 2019, are the first patents granted in Lexaria’s second and third patent families which differ from the Company’s original patent family, “Food and beverage compositions infused with lipophilic active agents and methods of use thereof” under which 14 of Lexaria’s patents have been granted.
More significantly the patents granted under these two new patent families include claims for the use of DehydraTECH technology with respect to not only food and beverage use, but for the first time also for pharmaceutical applications for:
- delivery of cannabinoids as methods of treating certain conditions including, but not limited to, heart disease; neurological diseases such as Alzheimer’s, Parkinson’s, schizophrenia, and human immunodeficiency virus (HIV) dementia; obesity, metabolic disorders, hepatic diseases, diabetes, appetite disorders, cancer via chemotherapy, irritable bowel syndrome (IBS), marijuana abuse, and alcohol, opioid, nicotine or cocaine addiction.
Claims granted in these two new patent families specify a wide range of delivery formats, including but not limited to dry beverages such as coffee, tea and hot chocolate; ready-to-drink beverages such as carbonated and non-carbonated beverages, fruit, citrus or vegetable beverages, dairy beverages, energy, sports and protein drinks, and flavoured water; foods and foodstuffs such as pastas, breads, grains, seeds, spices and more; and a range of pharmaceutical compositions such as tablets, pills, capsules, liquids, gels, syrups and slurries.
Claims granted also respect a broad range of therapeutically active substances including cannabinoids; nicotine; non-steroidal anti-inflammatory drugs (NSAIDs) such as acetylsalicylic acid, ibruprofen, diclofenac, indomethacin, and piroxicam; and fat-soluble vitamins including Vitamin E.
Lexaria now holds granted patents in three patent families, which now also includes claims for potential treatment of disease conditions. Lexaria currently has approximately 60 patent applications pending across 10 different patent families.
For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)
and on Facebook https://www.facebook.com/lexariabioscience/
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(250) 765-6424 ext. 202
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids, nicotine or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
SOURCE: Lexaria Bioscience Corp.
View source version on accesswire.com:
Released August 27, 2019